Clinical trial: intravenous pantoprazole vs. ranitidine for the prevention of peptic ulcer rebleeding: a multicentre, multinational, randomized trial

Summary Background  Controlled pantoprazole data in peptic ulcer bleeding are few. Aim  To compare intravenous (IV) pantoprazole with IV ranitidine for bleeding ulcers. Methods  After endoscopic haemostasis, 1256 patients were randomized to pantoprazole 80 mg+8 mg/h or ranitidine 50 mg+13mg/h, both...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2009-03, Vol.29 (5), p.497-507
Main Authors: VAN RENSBURG, C., BARKUN, A. N., RACZ, I., FEDORAK, R., BORNMAN, P. C., BEGLINGER, C., BALANZÓ, J., DEVIÈRE, J., KUPCINSKAS, L., LUEHMANN, R., DOERFLER, H., SCHÄFER‐PREUSS, S.
Format: Article
Language:English
Subjects:
2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage
Adolescent
Adult
Aged
Anti-Ulcer Agents - administration & dosage
Biological and medical sciences
Digestive system
Double-Blind Method
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Injections, Intravenous
Medical sciences
Middle Aged
Other diseases. Semiology
Peptic Ulcer Hemorrhage - drug therapy
Peptic Ulcer Hemorrhage - prevention & control
Pharmacology. Drug treatments
Ranitidine - administration & dosage
Secondary Prevention
Statistics as Topic
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background  Controlled pantoprazole data in peptic ulcer bleeding are few. Aim  To compare intravenous (IV) pantoprazole with IV ranitidine for bleeding ulcers. Methods  After endoscopic haemostasis, 1256 patients were randomized to pantoprazole 80 mg+8 mg/h or ranitidine 50 mg+13mg/h, both for 72 h. Patients underwent second‐look endoscopy on day 3 or earlier, if clinically indicated. The primary endpoint was an overall outcome ordinal score: no rebleeding, rebleeding without/with subsequent haemostasis, surgery and mortality. The latter three events were also assessed separately and together. Results  There were no between‐group differences in overall outcome scores (pantoprazole vs. ranitidine: S0: 91.2 vs. 89.3%, S1: 1.5 vs. 2.5%, S2: 5.4 vs. 5.7%, S3: 1.7 vs. 2.1%, S4: 0.19 vs. 0.38%, P = 0.083), 72‐h clinically detected rebleeding (2.9% [95% CI 1.7, 4.6] vs. 3.2% [95% CI 2.0, 4.9]), surgery (1.9% [95% CI 1.0, 3.4] vs. 2.1% [95% CI 1.1, 3.5]) or day‐3 mortality (0.2% [95% CI 0, 0.09] vs. 0.3% [95% CI 0, 1.1]). Pantoprazole significantly decreased cumulative frequencies of events comprising the ordinal score in spurting lesions (13.9% [95% CI 6.6, 24.7] vs. 33.9% [95% CI 22.1, 47.4]; P = 0.01) and gastric ulcers (6.7% [95% CI 4, 10.4] vs. 14.3% [95% CI 10.3, 19.2], P = 0.006). Conclusions  Outcomes amongst pantoprazole and ranitidine‐treated patients were similar; pantoprazole provided benefits in patients with arterial spurting and gastric ulcers.
ISSN:0269-2813
1365-2036
DOI:10.1111/j.1365-2036.2008.03904.x